Alar Pharmaceuticals Inc. has received notice of allowance for a patent in Taiwan. The patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES, applied by Alar Pharmaceuticals Inc. has received notice of allowance from Taiwan Intellectual Property Office (TIPO). Granding above patent by the Company will facilitate the international licensing business.

It takes a considerable time to develop a new drug and the cost of development is relatively high. The success of the development is not guaranteed. The investors shall bear the investment risk and judge the investment with caution.